Strategic Execution and Platform Validation
-
Established a transformative partnership with Dynavax (now a Sanofi company) for the oral COVID-19 vaccine, providing $30,000,000 in immediate capital and up to $700,000,000 in total potential value.
-
Validated the oral vaccine platform's potential for passive immunity transfer through a published study showing maternal IgA antibodies in infant stool following norovirus vaccination.
-
Demonstrated superior immunogenicity of second-generation norovirus constructs, which achieved up to a 141% increase in antibody response compared to original formulations.
-
Implemented a disciplined capital allocation strategy by terminating a long-term lease early to reduce operating expenses and extend the cash runway into 2027.
-
Integrated second-generation technology across the entire pipeline, including COVID-19 and flu candidates, to leverage proven increases in immune response.
-
Maintained a productive collaboration with BARDA to navigate the amended Phase 2b COVID-19 trial following a prior stop-work order.
Clinical Milestones and Partnership Strategy
-
Expects to report 12-month top-line safety and initial efficacy data from the 400-subject COVID-19 sentinel cohort in early Q2 2026.
-
Anticipates reporting robust efficacy data from the 5,000-subject KP2 COVID-19 cohort in late 2026, subject to BARDA approval.
-
Prioritizing the securing of a strategic partner or non-dilutive funding to initiate the next clinical trial for second-generation norovirus constructs in 2026.
-
Conducting preclinical studies to evaluate G24 construct cross-reactivity against the G217 norovirus strain to broaden the vaccine's market utility.
-
Actively pursuing licensing opportunities for earlier-stage assets, including seasonal flu, pandemic flu, and HPV programs.
Operational and Structural Updates
-
The acquisition of Dynavax by Sanofi in February 2026 positions Vaxart to work with a global vaccine leader on its COVID-19 candidate.
-
A lease termination agreement effective May 2026 will accelerate the exit from a facility originally contracted through 2029 to preserve cash.
-
Revenue surged to $237,300,000 in 2025, primarily driven by BARDA contract milestones and the Dynavax upfront payment.
-
The Phase 2b COVID-19 trial was modified by BARDA to focus on the 5,400 subjects already enrolled rather than the original 10,000-subject target.
Q&A Session Insights
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Timeline shift and expectations for the 400-person sentinel cohort
-
Management confirmed the data release shifted from late Q1 to early Q2 2026 due to the collaborative review process with BARDA.
-
The cohort is primarily designed to assess safety, though it will provide some initial insights into efficacy measures.
Immunogenicity data timing for COVID-19 and KP2 cohorts
-
Immunogenicity results will lag behind top-line safety and efficacy data because the analysis is primarily executed by BARDA partners.
-
This phased data release approach is expected for both the 400-person sentinel and the 5,000-person KP2 cohorts.
Regulatory status and endpoints for the norovirus program
-
Vaxart has held discussions with the FDA regarding the next Phase 2 study, which will focus on safety and immunogenicity endpoints.
-
Advancement into the next clinical phase remains contingent on securing a partner or additional funding.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
